Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2018
NICE approves CDF funding for Janssen’s Darzalex
17 January 2018 - NICE is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund for some adults ...
Posted by Michael Wonder on 10 Jan 2018
NICE backs wider use of MSD’s Simponi
10 January 2018 - Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi ...
Posted by Michael Wonder on 08 Jan 2018
NICE to look again at Pfizer’s Besponsa after appeal
3 January 2018 - The blood cancer medicine was originally turned down on cost-effectiveness grounds. ...
Posted by Michael Wonder on 05 Jan 2018
NICE final draft guidance recommends gene therapy for rare ‘bubble baby syndrome’
3 January 2018 - Strimvelis, a treatment for an ultra-rare inherited immune deficiency condition that has been dubbed ‘bubble baby syndrome’ ...
Posted by Michael Wonder on 21 Dec 2017
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance
20 December 2017 - Multiple sclerosis drug, Extavia, has been approved for routine funding on the NHS, in NICE draft guidance. ...
Posted by Michael Wonder on 20 Dec 2017
NICE turns down rare skin disease implant
20 December 2017 - The National Institute for Health and Care Excellence has rejected Clinuvel UK’s afamelanotide for treating erythropoietic ...
Posted by Michael Wonder on 20 Dec 2017
Takeda’s Ninlaro approved for NHS use via Cancer Drugs Fund
20 December 2017 - Patients in England and Wales will now be able to access Takeda’s myeloma treatment Ninlaro on ...
Posted by Michael Wonder on 14 Dec 2017
NICE changes its mind on Imbruvica for mantle cell lymphoma
14 December 2017 - In a reversal of a previous guidance, the UK’s NICE has issued draft guidance recommending ibrutinib ...
Posted by Michael Wonder on 12 Dec 2017
Final NHS ‘no’ for obesity pill Mysimba
12 December 2017 - An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, ...
Posted by Michael Wonder on 11 Dec 2017
NICE U-turn backs combo for kidney cancer
11 December 2017 - In a turnaround from its earlier position, the NICE is now endorsing NHS funding for Eisai’s ...
Posted by Michael Wonder on 09 Dec 2017
NICE nods for AbbVie in hepatitis C and Novartis in lung cancer
8 December 2017 - NICE has published new draft guidance for Novartis' Zykadia and AbbVie's Maviret. ...
Posted by Michael Wonder on 05 Dec 2017
Novartis and Roche get NICE rejections
5 December 2017 - There was disappointing news today for Swiss pharma giants Novartis and Roche when the UK’s NICE ...
Posted by Michael Wonder on 27 Nov 2017
NICE no for Halaven in new indication
27 November 2017 - A lack of clinical evidence proving its effectiveness has led NICE to publish draft guidance refusing ...
Posted by Michael Wonder on 23 Nov 2017
Roche’s Erivedge no longer funded by the NHS
23 November 2017 - Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment ...
Posted by Michael Wonder on 20 Nov 2017
Bayer’s Stivarga wins NICE approval for GIST
20 November 2017 - Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a ...